David Garrett, VP of Finance and Corporate Development at Dipexium Pharmaceuticals Inc (DPRX), says its lead candidate, Locilex, is going after a very large market. Locilex is a broad-spectrum topical antibiotic cream for the treatment of patients with mild infections of diabetic foot ulcers.
“In the mild category, which represents about 47% of the population — in other words, 47% of patients who have a DFI first present to a treating physician at the mild stage — that 47% equates to about 650,000 patients per year in the U.S. alone. We expect to become the standard of care in mild DFI,” Garrett says.
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Garrett adds that currently, there is no product approved by the FDA specifically for mild DFI, and no topical antibiotic approved in any category of DFI.
“In terms of differentiation, there are three key attributes that separate Locilex from other products. First, Locilex has an extremely broad spectrum of activity; that is, it kills gram-positive, gram-negative, aerobic and anaerobic bacteria, as well as numerous different kinds of multidrug-resistant bacteria,” Garrett says. “Second, Locilex is a topical cream that does not absorb into the blood stream, which we believe has the potential to be an extremely safe and well-tolerated product…Lastly, as Locilex does not absorb into the blood stream, we have seen no evidence to date of bacteria developing systemic resistance to Locilex.”
Novo Nordisk A/S (ADR) (NVO) Plays to Underlying Health Care Trends as the World Leader in Diabetic Care
October 01, 2013
Buffalo Wild Wings (BWLD) Maintains 20% Unit Level EBITDA Profitability with $300 Sales per Square Foot
March 12, 2013
Microchip Technology Inc. (MCHP) Expects Spike in Margins After Meeting Inventory Goals
May 30, 2013
Spirit Realty Capital, Inc. (SRC) CEO Expects Substantial Growth for Net-Lease REITs
December 23, 2015
Anadarko Petroleum Corporation (APC) Explores for Gas in East Africa and Expects Benign Tronox Resolution
February 12, 2013
